

Resource Summary Report

Generated by [FDI Lab - SciCrunch.org](#) on Apr 22, 2025

rat IgG2b I sotype control

RRID:AB_1107780

Type: Antibody

Proper Citation

(Bio X Cell Cat# BE0090, RRID:AB_1107780)

Antibody Information

URL: http://antibodyregistry.org/AB_1107780

Proper Citation: (Bio X Cell Cat# BE0090, RRID:AB_1107780)

Target Antigen: KLH

Host Organism: rat

Clonality: isotype control

Antibody Name: rat IgG2b I sotype control

Description: This isotype control targets KLH

Clone ID: clone LTF-2

Antibody ID: AB_1107780

Vendor: Bio X Cell

Catalog Number: BE0090

Alternative Catalog Numbers: BE0090-50MG, BP0090-50MG, BP0090-25MG, BE0090-100MG, BP0090-5MG, BE0090-1MG, BE0090-25MG, BP0090-100MG, BE0090-5MG

Record Creation Time: 20231110T031638+0000

Record Last Update: 20240725T040953+0000

Ratings and Alerts

No rating or validation information has been found for rat IgG2b I sotype control.

No alerts have been found for rat IgG2b I sotype control.

Data and Source Information

Source: [Antibody Registry](#)

Usage and Citation Metrics

We found 176 mentions in open access literature.

Listed below are recent publications. The full list is available at [FDI Lab - SciCrunch.org](#).

Cha J, et al. (2024) Skin microbe-dependent TSLP-ILC2 priming axis in early life is co-opted in allergic inflammation. *Cell host & microbe*, 32(2), 244.

Kumar S, et al. (2024) Uncovering therapeutic targets for macrophage-mediated T cell suppression and PD-L1 therapy sensitization. *Cell reports. Medicine*, 5(9), 101698.

Yu J, et al. (2024) Progestogen-driven B7-H4 contributes to onco-fetal immune tolerance. *Cell*, 187(17), 4713.

Porier DL, et al. (2024) Humoral and T-cell-mediated responses to an insect-specific flavivirus-based Zika virus vaccine candidate. *PLoS pathogens*, 20(10), e1012566.

Pal R, et al. (2024) Fluorescence Lifetime Imaging Enables In vivo Quantification of PD-L1 Expression and Inter-tumoral Heterogeneity. *Cancer research*.

Huang CX, et al. (2024) Pericancerous cross-presentation to cytotoxic T lymphocytes impairs immunotherapeutic efficacy in hepatocellular carcinoma. *Cancer cell*, 42(12), 2082.

Feng S, et al. (2024) Blockage of L2HGDH-mediated S-2HG catabolism orchestrates macrophage polarization to elicit antitumor immunity. *Cell reports*, 43(6), 114300.

Lim RJ, et al. (2024) CXCL9/10-engineered dendritic cells promote T cell activation and enhance immune checkpoint blockade for lung cancer. *Cell reports. Medicine*, 5(4), 101479.

He C, et al. (2024) UFL1 ablation in T cells suppresses PD-1 UFMylation to enhance anti-tumor immunity. *Molecular cell*, 84(6), 1120.

Yang Y, et al. (2024) Dietary vitamin B3 supplementation induces the antitumor immunity against liver cancer via biased GPR109A signaling in myeloid cell. *Cell reports. Medicine*, 5(9), 101718.

Chun D, et al. (2024) Flt3L enhances clonal diversification and selective expansion of intratumoral CD8+ T cells while differentiating into effector-like cells. *Cell reports*, 43(12),

115023.

Wang C, et al. (2024) Circadian tumor infiltration and function of CD8+ T cells dictate immunotherapy efficacy. *Cell*, 187(11), 2690.

Jaeger-Ruckstuhl CA, et al. (2024) Signaling via a CD27-TRAF2-SHP-1 axis during naive T cell activation promotes memory-associated gene regulatory networks. *Immunity*, 57(2), 287.

Liu J, et al. (2024) QDPR deficiency drives immune suppression in pancreatic cancer. *Cell metabolism*, 36(5), 984.

Mahadevan KK, et al. (2024) Type I conventional dendritic cells facilitate immunotherapy in pancreatic cancer. *Science (New York, N.Y.)*, 384(6703), eadh4567.

Joshi S, et al. (2024) Tim4 enables large peritoneal macrophages to cross-present tumor antigens at early stages of tumorigenesis. *Cell reports*, 43(4), 114096.

Bejarano L, et al. (2024) Interrogation of endothelial and mural cells in brain metastasis reveals key immune-regulatory mechanisms. *Cancer cell*, 42(3), 378.

Li Y, et al. (2024) Tumor cells impair immunological synapse formation via central nervous system-enriched metabolite. *Cancer cell*, 42(6), 985.

Meza-Perez S, et al. (2024) Proteobacteria impair anti-tumor immunity in the omentum by consuming arginine. *Cell host & microbe*, 32(7), 1177.

Ziblat A, et al. (2024) Batf3+ DCs and the 4-1BB/4-1BBL axis are required at the effector phase in the tumor microenvironment for PD-1/PD-L1 blockade efficacy. *Cell reports*, 43(5), 114141.